PRI 724

Drug Profile

PRI 724

Alternative Names: PRI-724

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator PRISM BioLab; University of Southern California
  • Developer inVentiv Health; PRISM Pharma Co; Tokyo Metropolitan Komagome Hospital
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Phase I Hepatic fibrosis; Pancreatic cancer; Solid tumours

Most Recent Events

  • 13 Apr 2017 University of Southern California withdraws prior to enrolment the phase II PREMIER trial for Colorectal cancer in USA (NCT02413853)
  • 30 Dec 2016 Prism Pharma completes a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) and Chronic myeloid leukaemia (Second-line therapy or greater) in USA (NCT01606579)
  • 11 Nov 2016 Initial efficacy and adverse events data from a phase I trial in Hepatic fibrosis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top